EXOZYMES INC.

Nasdaq:EXOZ

Biological Products, (No Diagnostic Substances)·MONROVIA, CA

CEO

Heltzen Michael

Summary Financials

Revenue

$70,069

FY 2024

Adj. EBITDA

-$1.6M

-2282.4% margin

FY 2024

Net Income

-$2.0M

-2909.1% margin

FY 2024

EPS (Diluted)

-$0.33

FY 2024

Stock Price

$7.31

-2.8%

2026-03-06

52W Range

$7.08 – $18.40

P/E Ratio

-22.2x

Market Cap

$61.3M

Cash

$66,533

FY 2024

Total Debt

—

Net Cash

$66,533

FY 2024

Enterprise Value

$61.3M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-38.3x

Employees

—

Revenue

$70,069

FY 2024

Adj. EBITDA

-$1.6M

-2282.4% margin

FY 2024

Net Income

-$2.0M

-2909.1% margin

FY 2024

EPS (Diluted)

-$0.33

FY 2024

Stock Price

$7.31

-2.8%

2026-03-06

52W Range

$7.08 – $18.40

P/E Ratio

-22.2x

Market Cap

$61.3M

Cash

$66,533

FY 2024

Total Debt

—

Net Cash

$66,533

FY 2024

Enterprise Value

$61.3M

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

-38.3x

Employees

—